Medicus Pharma Ltd.
June 24, 2026
Theater 2
Type: Company Presentation
Focus Area:
Other
Medicus Pharma Ltd. (NASDAQ:MDCX) is a precision guided biotech/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutic assets designed to transform the standard of care. The company is actively engaged in multiple countries spread over three continents.
Our strategy is to advance select programs through Phase 2 proof-of-concept and pursue licensing or strategic partnerships with established pharmaceutical companies that are best positioned to conduct late-stage development and commercialization. Our Phase 2 studies are designed to generate decision-grade clinical, regulatory and operational data packages intended to support partnering discussions and potential licensing transactions.
We look into opportunities where an unmet need exists for improved patient safety and efficacy.
Company HQ City:
Woodbury
Company HQ State:
MN
Company HQ Country:
United States
Year Founded:
2023
Lead Product in Development:
Skinject, Teverelix
CEO
Raza Bokhari
Development Phase of Lead Product
Phase II
Exchange
Nasdaq
Ticker
MDCX
When you expect your next catalyst update?
end of 2026
What is your next catalyst (value inflection) update?
End-of-Phase 2 FDA meeting for SkinJect™ to define the registrational pathway.
Initiation of Phase 2b Teverelix study in advanced prostate cancer.
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}